Invention Grant
- Patent Title: Extended release formulation of a direct thrombin inhibitor
-
Application No.: US14356833Application Date: 2012-11-06
-
Publication No.: US10016417B2Publication Date: 2018-07-10
- Inventor: Sankar Ramakrishnan , Elumalal Venkatesan , Jayanthi Suryakumar , Stephane Allard
- Applicant: Diakron Pharmaceuticals Inc.
- Applicant Address: US NJ Morris Plains
- Assignee: Diakron Pharmaceuticals, Inc.
- Current Assignee: Diakron Pharmaceuticals, Inc.
- Current Assignee Address: US NJ Morris Plains
- Agency: Knobbe, Martens, Olson & Bear, LLP
- International Application: PCT/US2012/063734 WO 20121106
- International Announcement: WO2013/070623 WO 20130516
- Main IPC: A61K31/497
- IPC: A61K31/497 ; A61K9/20
Abstract:
Extended release formulations of 3-fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide (DPOC-4088) that provide for better control of blood plasma levels. The extended release formulations maintain substantially constant plasma levels of the active ingredient for at least about 16 hours and provide for once-daily dosing.
Public/Granted literature
- US20140309239A1 EXTENDED RELEASE FORMULATION OF A DIRECT THROMBIN INHIBITOR Public/Granted day:2014-10-16
Information query
IPC分类:
